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Biophysical Journal Volume 107 October 2014 1491–1492 1491New and NotableFIGURE 1 A central role for BAK in cytochrome-c release triggered by Ab1–42 oligomers. BAK
oligomerization and pore formation in the mitochondrial outer membrane are triggered by
interactions with either tBID or Ab1–42 oligomers. Cytochrome c released through the BAK pore
becomes an integral part of the apoptosome complex, which also includes APAF-1 and pro-caspase-9
(not shown). The apoptosome activates the intrinsic initiator caspase-9, which, in turn, cleaves and
activates the executioner caspase-3, leading to apoptotic cell death. To see this figure in color,
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Intrinsic apoptosis is initiated by the
BAX- or BAK-dependent permeabili-
zation of the mitochondrial outer
membrane and subsequent release of
cytochrome c. In Alzheimer’s disease
(AD), significant death of hippocam-
pal and cortical neuronal populations
occurs through multiple processes in-
cluding activation of the intrinsic
apoptosis pathway (1). In particular,
the expression of BAK is upregulated
in AD hippocampal and cortical tissues
when compared to age-matched con-
trol tissues (2,3). Prior studies have
demonstrated that amyloid beta pep-
tide 1–42 (Ab1–42) oligomers induce
cytochrome-c release and neuronal
apoptosis via a BAX-dependent mech-
anism (4). In this issue of the
Biophysical Journal, Kim et al. (5)
identify a significant role for BAK
in cytochrome-c release induced by
Ab1–42 oligomers. The authors
demonstrate that Ab1–42 oligomer-
induced HT22 hippocampal cell death
is significantly reduced by siRNA
knockdown of BAK. Moreover, mito-
chondria isolated from BAK knock-
down HT22 cells display reduced
cytochrome-c release in vitro in
response to either Ab1–42 oligomers
or truncated BID (tBID).
Most impressively, the authors have
developed a cell-free, liposome-based,
fluorescence cytochrome-c release
assay by which single vesicle release
events can be accurately recorded andhttp://dx.doi.org/10.1016/j.bpj.2014.08.012
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0006-3495/14/10/1491/2 $2.00monitored over time. They carefully
validate this assay using BAKDC-
term and tBID recombinant proteins
and convincingly show that Ab1–42
oligomers are capable of inducing
cytochrome-c release from BAKDC-
term-containing vesicles as well as
enhancing release in the presence of
tBID. Finally, they show that Ab1–42
oligomers bind directly to BAKDC-
term-containing vesicles but do not
bind as significantly to vesicles con-
taining tBID or protein-free liposomes.
In regard to this latter point, although
the authors suggest that the relatively
weak binding of Ab1–42 oligomers
to protein-free liposomes represents
nonspecific binding, this may in fact
not be the case.
Many previous studies have demon-
strated that Ab1–42 (or Ab1–40) olig-
omers interact directly with lipid
membranes and that these interactions
are significantly influenced by a
number of factors including oligomerconcentration, Ab1–40/Ab1–42 ratio,
cholesterol content, and charge on
both the lipid surface and the pep-
tide (6–10). It would be interesting
to examine how these different fac-
tors influence the Ab1–42 oligomer
interaction with BAK because the olig-
omerization process can be signifi-
cantly modulated by the specific
interactions of the Ab1–42 peptide
with the lipid membrane.
We believe the results presented
by Kim et al. (5) are novel and
clearly demonstrate a central role for
BAK in cytochrome-c release trig-
gered by Ab1–42 oligomers (Fig. 1).
This is in contrast to previous
studies suggesting that Ab1–42 (or
Ab1–40) oligomers induce direct
permeabilization of mitochondrial or
other lipid membranes in the absence
of any membrane-associated proteins
1492 Linseman(11,12). However, these prior studies
used much higher concentrations of
Ab oligomers, which might account
for the differences observed. Fur-
thermore, the development of a
liposome-based, fluorescence cyto-
chrome-c release assay by which
single vesicle release events can be
monitored over time represents a sig-
nificant technological advance that
will allow the probing of additional
pathways which regulate this process.
Future studies that examine, in more
detail, the mechanism by which
Ab1–42 oligomers activate BAK will
be informative. Finally, the findings
of Kim et al. (5) suggest that BAK
may be a new therapeutic target for
AD, and should prompt investigation
into the effects of crossing BAK
knockout mice with transgenic mouse
models of high Ab1–42 content such
as the APPswe/PSEN1dE9 (APP/
PS1) mouse.Biophysical Journal 107(7) 1491–1492REFERENCES
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